Company intelligence / Profile preview
Neurizon Therapeutics
South Melbourne, Victoria, Australianeurizon.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Neurizon Therapeutics’ lead candidate NUZ‑001 has shown positive safety and tolerability in a completed Phase I trial in ALS patients. The drug is entering a regimen-specific arm of the HEALEY ALS Platform Trial at Massachusetts General Hospital for a pivotal Phase II/III study starting in 2025. Preclinical studies have demonstrated significant blood–brain barrier penetration and neuroprotective effects across multiple neurodegenerative models. The company holds Orphan Drug Designation from both the FDA and EMA for ALS.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Syngene International Ltd.Catalent Inc.Massachusetts General Hospital / HEALEY ALS Platform Trial
Beyond the preview
Go deeper on Neurizon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurizon Therapeutics.